

EXO-METABOLOMICS FINGERPRINT OF BLADDER CANCER PROGRESSION USING 1H-NMR

Invasive and non-invasive tumour cells show two different metabolisms

G. Ciufolini, ‡ G. Petrella, ‡ R. Vago, † D.O. Cicero, ‡

‡ Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma “Tor Vergata”, 00133 Rome, Italy

† Urological Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy; Faculty of Medicine and Surgery, Università Vita-Salute San Raffaele, 20132 Milan, Italy

E-mail: giorgia.ciufolini@live.com



Introduction

- Urothelial bladder cancer (UBC) is the most common tumor of the urinary system.
- Divided into low-grade non-muscular invasive bladder cancer (**NMIBC**) and high-grade muscular invasive bladder cancer (**MIBC**).
- Problem: **lack of prognostic markers** that can anticipate the progression of the cancer.

Aim

Investigate the correlation between different risks of progression and cells metabolism, in order to provide new prognostic markers for in vivo analysis.

In this study, we used ¹H-NMR to characterize the intake of nutrients and the excretion of products in the extracellular medium of three urothelial bladder cancer cell lines (UBCcls).

Methods


Cells were grown in RPMI culture medium for 1, 2 or 3 days in separated containers.



Cellular model that may represent different types of tumors ^{1, 2, 3}


UBCcls	Genetic alteration	Genetic instability	Model	Risk of progression
5637	TP53 mut	++	Aggressive	High
RT112	TP53/FGFR3 mut	+	Non-aggressive	Unknown
RT4	FGFR3 mut	+	Non-aggressive	Low

Results: Exo-metabolomic profile




Normalization	Composition (w _{wt})									Intrinsic rate (q _{wt})								
Cell line	5637			RT112			RT4			5637			RT112			RT4		
Day	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3
Choline																		
Glucose																		
Glutamine																		
Histidine																		
Isoleucine																		
Leucine																		
Methionine																		
Myo-Inositol																		
Acetylcholine																		
Pyridoxine																		
Serine																		
Tryptophan																		
Tyrosine																		
Valine																		
Alanine																		
Formate																		
Lactate																		
Pyruvate																		
Arginine																		
Asparagine																		
Aspartate																		
Creatinine																		
Cystine																		
Fructose																		
Fumarate																		
Glutamate																		
Glycine																		
Lysine																		
Ornithine																		
Phenylalanine																		
Proline																		
Pyroglutamate																		
Succinate																		
t-4-OH-proline																		
Threonine																		

OPLS-DA separation due to pyruvate and serine metabolisms, arginine, glutamine, and BCAAs.




Good predictive power (Q²=0.868) and highly significant (CV-ANOVA=8.0E-05).


Lactate/Alanine: Degree of glycolysis and OxPhos



Invasive cells consume almost exclusively glucose and excrete lactate



Non-invasive cells show mitochondrial activity



Differently regulated biochemical pathways in the UBCcls


NON INVASIVE BC

Glycolysis metabolism

INVASIVE BC



OxPhos metabolism

The Interplay between Oxidative Phosphorylation and Glycolysis as a Potential Marker of Bladder Cancer Progression



Two classes of cancer metabolism

- INVASIVE CANCER
- LOW OXIDATIVE METABOLISM
- HIGH RISK OF PROGRESSION
- MUTATION OF TP53 GENE
- NON INVASIVE CANCER
- ACTIVE OXIDATIVE METABOLISM
- LOW RISK OF PROGRESSION
- MUTATION OF FGFR3 GENE



First time the importance of oxidative phosphorylation for BC cells has been observed.

References

1 - Earl et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics 16, (2015)
2 - Simabuco et al. p53 and metabolism: from mechanism to therapeutics. Oncotarget 9 (34), 23780-23823. (2018)
3 - Frattini et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature, 553,222-227 (2018).